Actively Protective Biology

Maximizing longevity and healthspan

Chronic diseases are becoming the greatest threat to global health – affecting billions of people, driving over 80% of healthcare costs, and placing unsustainable pressure on health systems.

New preventative health approaches are urgently required to reduce the global burden of complex chronic diseases.

At PrecisionLife, we’ve identified a new class of actively protective drug targets – biological mechanisms that naturally defend against disease. These discoveries enable novel interventions to protect against disease and prevent disease progression.

This is the future of preventative healthcare and drug development.

Detecting mechanisms that prevent disease in high-risk individuals

Our platform identifies combinations of features that contribute to reducing risk of disease in individuals who remain healthy even though their genomic profile suggests that they have high risk of developing disease.

These protective signatures can be used to identify novel drug targets, pharmacogenomic and therapeutic mRNA opportunities, and to better stratify patients by overall disease risk and mechanistic subtype.

Identifying protected cohorts

We screen healthy populations against our risk models to find cohorts enriched in actively protective factors – subgroups that have the risk signatures which would normally result in disease, but have not been affected.

Finding protective signatures

By eliminating the disease associated risk genes we find the genes unique to the protected cohort, which appear to be protecting against the development of the disease, even in patients at high risk.

Selecting protective targets

We then conduct biological analyses to identify and characterize key genes, potential drug targets, genetic interactions, pathways, and mechanisms of action represented by the protective disease signatures.